A Multi-center RCT Trial on Prognosis of Patients With Anticoagulation and DAPT Therapy After LAAC

• Status: Unknown status
• Trial end date: 2020-11-30
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to assess the different dosage of rivaroxaban application versus dual antiplatelet therapy for prevention of device-related-thrombus in patients undergoing left atrial appendage closure using the WATCHMAN device.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Zhongshan Hospital
• Treatments: Rivaroxaban

Criteria

Inclusion Criteria:

• Successful transcatheter LAAC with any approved device

• Age18-75 years old

• Weight≥50kg

Exclusion Criteria:

• Absolute contraindications for anticoagulation therapy

• Prior intracranial hemorrhage

• Contraindications for TEE

• Severe pericardial effusion within the first 24 hrs following LAAC

• Major/life-threatening bleeding within the first 24 hrs following LAAC

• Female subjects of childbearing potential without using highly effective methods of contraception

• Serious renal insufficiency(CRCL<30ml/min)